Efficacy of the mouthwash CB12 in the treatment of intra-oral halitosis: a double-blind, randomised, controlled trial

Rainer Seemann, 1 Andreas Filippi, 2 Sebastian Michaelis, 3 Susanne Lauterbach, 4 Hans-Dieter John, 4 Jörg Huisman
1 Department of Preventive-, Restorative- and Pediatric Dentistry, ZMK Bern, University Bern, Switzerland; 2 Klinik für Zahnärztliche Chirurgie, Radiologie, Mund- und Kieferheilkunde und Zahnarztpraxis Nordstrasse, Düsseldorf, Germany; 3 Zahnarztpraxis Nordstrasse, Düsseldorf, Germany; 4 Periodontics Düsseldorf, Düsseldorf, Germany; 5 Köln-Deutz, Germany

Introduction

• The prevalence of halitosis in the general public is estimated at around 30%. 1,2 Around 90% of these halitosis cases are caused by volatile sulphur compounds (VSC) produced by anaerobic bacteria in the oral cavity (intra-oral halitosis). 3,4
• Organoleptic scoring by a trained odour judge is considered the gold standard for assessing breath odour; 5 but is subjective and difficult to standardise. 6 The OralChroma gas chromatograph and the Halimeter measure VSCs objectively and correlate well with organoleptic scores.
• CB12 (MEDA OTC Sweden) is an over-the-counter mouthwash containing zinc acetate (0.3%) and low concentration chlorhexidine (0.025%).
• The efficacy of CB12 in treating halitosis has been shown in several open label studies: 7–10

CB12 reduced halitosis more effectively than placebo (i.e. significantly greater inhibition of VSC production), without causing both discoloration, mucosal lesions or taste disturbance. 7–10

CB12 also reduced halitosis more effectively than five other mouthwash products (assessed by both organoleptic score and inhibition of VSC production) with superiority noted up to 3 hours. 7–10

Aim

• To establish the long-term (12 hour) efficacy of CB12 in a rigorous, state-of-the-art randomised, placebo-controlled, double blind, cross-over study in subjects with intra-oral halitosis.

Methods

• Eligible subjects were otherwise healthy but had halitosis of intra-oral origin with daily periods of noticeable halitosis; had an organoleptic score ≥2 and a total VSC >160 ppb, hydrogen sulphone ≥112 ppb and methyl mercaptan ≥26 ppb prior to first dose.
• Exclusion criteria included periodontitis, oral cavities lesions, obvious gingival inflammation or gingivitis, and oral thrush.

Subjects

• Eligible subjects were otherwise healthy but had halitosis of intra-oral origin with daily periods of noticeable halitosis; had an organoleptic score ≥2 and a total VSC >160 ppb, hydrogen sulphone ≥112 ppb and methyl mercaptan ≥26 ppb prior to first dose.
• Exclusion criteria included periodontitis, oral cavities lesions, obvious gingival inflammation or gingivitis, and oral thrush.

Study design

• Randomised, controlled, double-blind, two-sequence, three-fold replicate, crossover design
• Subjects were randomised 1:1 to receive:
  • CB12-water-water OR
  • water-CB12-CB12
• The second period was replicated to minimise possible carry-over effects between periods.
• Treatments were taken 12 hours apart and there was a 5-day washout between periods.
• The study was conducted in agreement with the ICH guideline on Good Clinical Practice (ICH E6) and other applicable guidelines.

Interventions

• All treatments were administered by rinsing 10 ml in the mouth for 30 seconds, as per the user instructions for CB12. The control treatment was non-carbonated water.
• Treatments were administered under supervised, controlled conditions.
• Subjects stayed in the study ward for the observational period of about 30 hours
• Smoking, foods associated with oral malodour, antibacterial lozenges and changes in oral hygiene practices were not permitted on study days or the preceding 48 hours.

Efficacy assessment

• Assessments were made of
  • Baseline (i.e. in the evening prior to first rinse),
  • 12 hours after first treatment (i.e. in the morning following night sleep; overnight assessment), and
  • 12 hours after second treatment (i.e. in the evening 24 hours after the first treatment; day 2 assessment).
  • Oral levels of hydrogen sulphone, methyl mercaptan and dimethyl sulphone were measured by OralChroma. Total VSC concentration was assessed by Halimeter.
• Organoleptic score was assessed by a trained odour judge using the 0-5 scale by Rosenberg (modified by Greeman): 0 = no odour, 1 = barely noticeable odour, 2 = slight odour, 3 = moderate odour, 4 = strong odour, 5 = very strong odour (saturation). 11

Statistical analyses

• The primary efficacy measure was hydrogen sulphone concentration and the co-primary measure was methyl mercaptan concentration, both after 12 hours (overnight assessment).
• The key secondary outcome measure was the change in organoleptic score from 0 hours to 12 hours.
• Analysis was performed for the intention-to-treat population (ITT; all subjects randomised and exposed to study treatment who had at least one assessment of efficacy), with a one-sided α-level of 2.5%.
• Safety was analysed in all randomised subjects who received at least one dose of study treatment.

Results

Baseline characteristics

• 34 subjects were randomised. Baseline data is provided in Table 1.

Table 1

<table>
<thead>
<tr>
<th>Baseline characteristics</th>
<th>Mean (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, n (%)</td>
<td>Male 17 (50)</td>
</tr>
<tr>
<td>Age, mean (range), years</td>
<td>44.2 (22-73)</td>
</tr>
<tr>
<td>DMFT index, mean (range)</td>
<td>12 (8-23)</td>
</tr>
<tr>
<td>Total Winkel score, mean (range)</td>
<td>4.3 (1-10)</td>
</tr>
</tbody>
</table>
| Mouth odor history, n (%) | Continuous mouth odor 12 (35.3%)
  Problems in morning and evening 12 (35.3%)
  Problems in morning only 12 (35.3%)
| Current use of products for mouth odor, n (%) | Mouth rinse products 33 (97)
Cheewing gum 23 (67.7)
Dental floss 19 (55.9)
Lozenges 17 (50)
| VSC concentration, ppb (SD) | CB12-Water/CB12-Water sequence (n=18) 204.8 (SD 300.6) CB12-Water/CB12 sequence (n=16) 206.8 (SD 300.6)

Statistical significance

• These results confirm findings from other CB12 studies.
• Use of CB12 was associated with a significant reduction in oral concentrations of hydrogen sulphone (Figure 1), methyl mercaptan (Figure 2), dimethyl sulphone and VSCs (halimeter) both overnight (12 hour after first dose) and during the 12 hour after the second dose.

Conclusions

• This well-designed, state-of-the-art study provides subjective and objective evidence that CB12 is an effective and long-lasting (at least 12 hours) treatment for halitosis, both overnight and during the day.
• These results confirm findings from other CB12 studies.
• So CB12 is backed by robust clinical data making it recommendable for evidence-based treatment of oral halitosis.

References